Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28058865 | 0.80 | ALDH1A1 (0.36) | SNCAALDH1A1HTTNAMPT | |
| SCHEMBL28100323 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2AHTTNAMPT | |
| SCHEMBL175786 | 0.75 | SNCA (0.67) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL254063 | 0.75 | CYP3A4 (0.59) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL5889082 | 0.75 | SNCA (0.54) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL2577778 | 0.75 | SNCA (0.54) | SNCACYP3A4ALDH1A1HSD17B10TSHR | |
| SCHEMBL29749636 | 0.75 | L3MBTL1 (0.37) | ALDH1A1TSHRKDM4EHPGDGAA | |
| Methyl Alcohol SCHEMBL29259257 | 0.75 | NAMPT (0.50) | CYP3A4ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL19100018 | 0.74 | LMNA (0.53) | CYP3A4ALDH1A1HSD17B10TSHRMEN1 | |
| SCHEMBL11786237 | 0.73 | NOS2 (0.46) | SNCACYP3A4ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| WO-2021137646-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | 주식회사 레고켐바이오사이언스 | 2021-07-08 | — | — | WO | disclosed |
| CN-107074863-B | Process for the preparation of ATR kinase inhibitors and different solid forms thereof | 沃泰克斯药物股份有限公司 | 2019-12-03 | — | — | CN | disclosed |
| CN-107074863-A | Radiolabeled derivatives of 2-amino-6-fluoro-N- [ 5-fluoro-pyridin-3-yl ] -pyrazolo [1,5-a ] pyrimidine-3-carboxamide compounds as ATR kinase inhibitors, processes for their preparation and their different solid forms | 沃泰克斯药物股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1756065-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115991-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310640-A1 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | BCR, PDCD1LG2, PRLHR | SNCA 3363/4885CYP3A4 616/4885ALDH1A1 1636/4885 |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL2 | SNCA 2176/4885CYP3A4 2056/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.